Cellectar Biosciences Reports Strong Phase 2 Data for Iopofosine I 131 in BTK-Resistant WM Patients
Event summary
- Cellectar Biosciences to present Phase 2 CLOVER WaM subset data at IWWM 2026, showing 79.2% major response rate and 87.5% overall response rate in BTK-resistant WM patients.
- Data supports plans for Phase 3 trial initiation and U.S. accelerated approval filing in 1H27.
- Iopofosine I 131 demonstrated duration of response exceeding 16 months in heavily pretreated WM patients.
- Presentation scheduled for October 15, 2026, at IWWM in Palm Springs, California.
The big picture
Cellectar's positive Phase 2 data for iopofosine I 131 in BTK-resistant WM patients represents a potential breakthrough in treating a challenging, heavily pretreated patient population. The results strengthen the company's case for accelerated approval and position it to compete in the WM therapy market, where BTK inhibitors have been the standard of care. The upcoming Phase 3 trial and regulatory filings will be critical in determining the drug's commercial potential.
What we're watching
- Regulatory Pathway
- Whether the Breakthrough Therapy Designation will accelerate iopofosine I 131's approval timeline beyond standard review processes.
- Clinical Execution
- The pace at which Cellectar can initiate and complete the Phase 3 confirmatory trial for WM indication.
- Market Positioning
- How these results will position iopofosine I 131 against existing BTK inhibitor therapies in the WM treatment landscape.
Related topics